amifostine anhydrous has been researched along with Cancer of Pelvis in 9 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Radiation colitis was assessed by clinical, endoscopic and histolopathological criteria." | 2.75 | Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis. ( Bai, M; Batistatou, A; Briasoulis, E; Capizzello, A; Christodoulou, D; Karavasilis, V; Katsanos, KH; Panelos, I; Tolis, C; Tsekeris, P; Tsianos, EV, 2010) |
| "A phase II trial of SC amifostine in head and neck cancer was performed in a patient population (n = 54) similar to that studied in a phase III trial of intravenous amifostine to allow comparisons of outcomes." | 2.70 | Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. ( Anné, PR, 2002) |
| "Mucositis is a significant complication of cancer therapy, with important clinical and economic implications." | 2.43 | Amifostine in the management of radiation-induced and chemo-induced mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006) |
| "Colitis was seen significantly lower in the radiation + gemcitabine + amifostine group (P = 0." | 1.35 | The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study. ( Altug, T; Atalar, B; Dinçbaş, FO; Gedik, N; Ilvan, S; Koca, S; Oksüz, DC; Ozel, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dinçbaş, FO | 1 |
| Oksüz, DC | 1 |
| Atalar, B | 1 |
| Altug, T | 1 |
| Ilvan, S | 1 |
| Gedik, N | 1 |
| Ozel, S | 1 |
| Koca, S | 1 |
| Katsanos, KH | 1 |
| Briasoulis, E | 1 |
| Tsekeris, P | 1 |
| Batistatou, A | 1 |
| Bai, M | 1 |
| Tolis, C | 1 |
| Capizzello, A | 1 |
| Panelos, I | 1 |
| Karavasilis, V | 1 |
| Christodoulou, D | 1 |
| Tsianos, EV | 1 |
| Koukourakis, MI | 2 |
| Kyrgias, G | 1 |
| Panteliadou, M | 1 |
| Papadopoulou, A | 1 |
| Tsiarkatsi, M | 1 |
| Papachristou, E | 1 |
| Bebeli, M | 1 |
| Anné, PR | 1 |
| Athanassiou, H | 1 |
| Antonadou, D | 1 |
| Coliarakis, N | 1 |
| Kouveli, A | 1 |
| Synodinou, M | 1 |
| Paraskevaidis, M | 1 |
| Sarris, G | 1 |
| Georgakopoulos, GR | 1 |
| Panousaki, K | 1 |
| Karageorgis, P | 1 |
| Throuvalas, N | 1 |
| Bensadoun, RJ | 1 |
| Schubert, MM | 1 |
| Lalla, RV | 1 |
| Keefe, D | 1 |
| Dest, VM | 1 |
| Stefanaki, I | 1 |
| Giatromanolaki, A | 1 |
| Frangiadaki, C | 1 |
| Armenaki, A | 1 |
| Georgoulias, V | 1 |
| Koumandakis, E | 1 |
| Kranidis, A | 1 |
| Helidonis, E | 1 |
| Niibe, H | 1 |
| Takahashi, I | 1 |
| Miyaishi, K | 1 |
| Mitsuhashi, N | 1 |
| Maehara, Y | 1 |
| Nakajima, N | 1 |
| Suto, H | 1 |
| Saito, Y | 1 |
| Yamakawa, M | 1 |
| Sugiyama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amifostine anhydrous and Cancer of Pelvis
| Article | Year |
|---|---|
Amifostine in the management of radiation-induced and chemo-induced mucositis.
Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophagitis; Evidence-Based Medicine; | 2006 |
Radioprotectants: adding quality of life to survivorship?
Topics: Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; O | 2006 |
6 trials available for amifostine anhydrous and Cancer of Pelvis
| Article | Year |
|---|---|
Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis.
Topics: Adult; Aged; Amifostine; Colitis; Combined Modality Therapy; Endometrial Neoplasms; Female; Follow-U | 2010 |
Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
Topics: Adult; Aged; Amifostine; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Dose-Respo | 2013 |
Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Topics: Adult; Aged; Amifostine; Cytoprotection; Dose Fractionation, Radiation; Female; Head and Neck Neopla | 2002 |
Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial.
Topics: Aged; Amifostine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Male; | 2003 |
Fractionated carboplatin radiosensitization: a phase I dose-escalation study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Erythropoiet | 1998 |
[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Double-Blind Method; Fe | 1985 |
1 other study available for amifostine anhydrous and Cancer of Pelvis
| Article | Year |
|---|---|
The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study.
Topics: Amifostine; Animals; Colitis; Collagen; Combined Modality Therapy; Cystitis; Deoxycytidine; Fibrosis | 2009 |